Exelixis (NASDAQ:EXEL) EVP Sells $2,187,757.85 in Stock

Posted by George Bondi on May 31st, 2026

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) EVP Dana Aftab sold 43,451 shares of Exelixis stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the sale, the executive vice president directly owned 594,741 shares of the company’s stock, valued at approximately $29,945,209.35. This trade represents a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Exelixis Trading Down 1.9%

Exelixis stock opened at $50.48 on Friday. Exelixis, Inc. has a 12-month low of $33.76 and a 12-month high of $52.96. The stock has a market cap of $12.69 billion, a P/E ratio of 16.77, a price-to-earnings-growth ratio of 1.06 and a beta of 0.38. The company has a fifty day simple moving average of $46.01 and a 200-day simple moving average of $44.22.

Exelixis (NASDAQ:EXEL – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The firm had revenue of $610.81 million during the quarter, compared to analysts’ expectations of $607.51 million. During the same period in the previous year, the company earned $0.55 earnings per share. Exelixis’s quarterly revenue was up 10.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Exelixis, Inc. will post 3.18 earnings per share for the current fiscal year.

Key Stories Impacting Exelixis

Here are the key news stories impacting Exelixis this week:

Positive Sentiment: Zacks Research raised several forward earnings estimates for Exelixis, including Q2 2026, Q3 2026, FY2026, FY2027, and FY2028, suggesting analysts see improving profitability ahead. Zacks Research estimate updates
Positive Sentiment: Exelixis said management will host fireside chats at upcoming June investor conferences, which can support investor confidence by highlighting strategy, pipeline progress, and commercial execution. Investor conference webcast announcement
Positive Sentiment: Wall Street commentary and fair-value updates have trended higher, with one article noting a refreshed fair value estimate near $49.65 and broader debate about Exelixis’s growth and competitive position. Fair value target article
Neutral Sentiment: Shareholders approved the company’s equity plan and board slate at the annual meeting, a routine governance update that removes an overhang but is not a major catalyst on its own. Shareholder approval article
Neutral Sentiment: Executive Vice President Dana Aftab sold 43,451 shares for about $2.19 million. Insider sales can weigh on sentiment, but this does not necessarily signal a change in the company’s fundamentals. Insider sale filing
Negative Sentiment: One Zacks note trimmed Q1 2027 EPS estimates slightly and maintained only a Hold rating, showing that not all analysts are turning more bullish. Zacks Hold rating and estimate cut

Analysts Set New Price Targets

A number of brokerages recently weighed in on EXEL. Stifel Nicolaus boosted their price target on shares of Exelixis from $44.00 to $47.00 and gave the company a “hold” rating in a research report on Wednesday, May 6th. Wells Fargo & Company boosted their price target on shares of Exelixis from $35.00 to $40.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Zacks Research cut shares of Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 5th. HC Wainwright boosted their price target on shares of Exelixis from $54.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Morgan Stanley boosted their price target on shares of Exelixis from $49.00 to $50.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $47.35.

Get Our Latest Stock Report on Exelixis

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Anchor Investment Management LLC increased its stake in Exelixis by 500.0% in the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 500 shares during the period. Motiv8 Investments LLC acquired a new position in Exelixis in the fourth quarter valued at $26,000. Cassaday & Co Wealth Management LLC acquired a new position in Exelixis in the first quarter valued at $27,000. Root Financial Partners LLC acquired a new position in Exelixis in the third quarter valued at $28,000. Finally, Western Wealth Management LLC acquired a new position in Exelixis in the first quarter valued at $29,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

About Exelixis

(Get Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.